Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2025-12-25 @ 1:18 AM
NCT ID:
NCT00388193
Eligibility Criteria:
Inclusion Criteria:
* Patients diagnosed with mature LLA-B cell (LLA-L3)
* Patients diagnosed with Burkitt´s and Burkitt´s Like Lymphoma
* Patients 15 years old or up
* Written Informed Consent signed
Exclusion Criteria:
* Serious complications related with LAL3/LB or Secondary illness:
Serious complications, uncontrollable, for example, sepsis, pneumonia with hypoxia, shock, haemorrhage at diagnosis.
* Renal failure unconditional for the Lymphoma/Leukemia
* Heart failure or serious liver.
* Pulmonary obstructive disease or serious restrictive that not allow to treat the patient with intensive chemotherapy.
* Secondary Lymphoma after chemotherapy or previous radiotherapy or second malignant tumour.
* Known hypersensitivity to any foreign protein.
* Previous treatment with cytostatics of the LLA-B or Burkitt´s Lymphoma (exception: administration on short time of glucocorticoids ≤ 7 days, one administration of vincristine or cyclophosphamide, one cycle of CHOP, urgent administration of the another cytostatics).
* With another malignant tumour in the last 5 year.
* Women in fertile age must give positive in the pregnancy test or nursing mother.
* Mental disability or emotional or psychiatric significant disorder were the patient can't understand nor cooperate with treatment.
* Patients is enrolled in another clinical research study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Study:
NCT00388193
Study Brief:
Protocol Section:
NCT00388193